Open AccessBlue-grey hyperpigmentation in acne after vandetanib therapy and doxycycline use: A case report
Author(s) -
Jonah Wiseman Perlmutter,
Rachel C Cogan,
Marni C. Wiseman
Publication year - 2022
Publication title -
sage open medical case reports
Language(s) - English
Resource type - Journals
ISSN - 2050-313X
DOI - 10.1177/2050313x221086316
Subject(s) - vandetanib , medicine , hyperpigmentation , dermatology , medullary thyroid cancer , acne , doxycycline , adverse effect , domperidone , cancer , thyroid cancer , tyrosine kinase , antibiotics , receptor , microbiology and biotechnology , biology , dopamine
Vandetanib is an oral tyrosine kinase inhibitor with cutaneous adverse effects that include the development of acne. We present a patient who underwent vandetanib therapy for stage IV medullary thyroid cancer in conjunction with the use of doxycycline for acne that developed. After vandetanib use, blue-grey pigmentation developed in the acne on his face, chest, back, and arms, which darkened after the use of doxycycline. We review the literature to report that this blue-grey hyperpigmentation was likely vandetanib-induced but may have been the result of both drugs being used in combination.